This was the stock's second consecutive day of gains.
4h
Zacks Investment Research on MSNWhy the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained TodayIn the latest market close, Vertex Pharmaceuticals (VRTX) reached $502.92, with a +1.51% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of ...
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
11h
MyChesCo on MSNVertex, Inc. Announces Investor Day Event with Live BroadcastVertex, Inc. (NASDAQ: VERX) has announced plans to host an Investor Day on Wednesday, March 19, in Philadelphia, PA. This ...
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...
KING OF PRUSSIA, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA. The event will ...
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
6d
MoneyWeek on MSNVertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results